chrisvoncsefalvay/vaers-outcomes huggingface dataset:
1/18 vaccination  Within 4 minutes, my husband started with tremors in his hand. Feeling funny. Felt like something was wrong. He was trying to hold hands still but then other extremities started to shake. He passed out. Honked for help. It took both ambulances to tx my husband and onto the stretcher and strapped in. Grand Mal Seizure. It started to fade when he got into but then had another one after he was in the ambulance, worse then the first one.  He continued to have seizures for 4 more days. Every couple hours, give him the kepra and topomax to help.  1/20 orthopedist 1/25 PCM 1/26 Neurologist 1/28 home health nurse 2/8 PCM, mental health 2/10 orthopedist 2/12 home health nurse  2/17 home health nurse  **stated he cannot have 2nd vaccine. 'if he has another grand mal seizure it will kill him'
sore arm; felt heavy arm; could not move arm; light headed; felt cold; headache and shooting pain in head; sit all day at work; injection site pain; This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 53-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 12th June 2019, the patient received the 1st dose of Shingrix. On 12th June 2019, less than a day after receiving Shingrix, the patient experienced injection site pain. On 13th June 2019, 1 day after receiving Shingrix, the patient experienced pain in arm, heaviness in arm, mobility decreased, light headedness, feeling cold, headache and loss of personal independence in daily activities. On 14th June 2019, the outcome of the pain in arm, heaviness in arm, mobility decreased, light headedness, feeling cold, headache and loss of personal independence in daily activities were recovered/resolved. On 16th June 2019, the outcome of the injection site pain was recovered/resolved.   It was unknown if the reporter considered the pain in arm, heaviness in arm, mobility decreased, light headedness, feeling cold, headache, injection site pain and loss of personal independence in daily activities to be related to Shingrix.  Additional details were provided as follows: The patient received the vaccine on left arm, last Wednesday evening from the day of reporting and woke up Thursday morning with a sore arm that felt heavy. The patient couldn't move it and that day he felt light headed to the point that he had to sit at work all day. The patient also had a headache and felt cold and needed to wear a jacket all day.  He had a shooting pain in his head every time he turned his head.  All the symptoms continued through out the day on Thursday from the day of reporting.  On Friday, most symptoms had resolved but the patient still had a slight headache and was slightly lightheaded.   By Friday evening slight headache and was slightly lightheaded was resolved. The only symptom that did not resolve was the soreness at the injection site. That symptom resolved by Sunday night. The reporter consented to follow up.; Sender's Comments: The patient received the vaccine last Wednesday evening and woke up Thursday morning with a sore arm that felt heavy.  He couldn't move it.  That day he felt light headed to the point that he had to sit at work all day.  He also had a headache and felt cold and needed to wear a jacket all day.  He had a shooting pain in his head every time he turned his head. All the symptoms continued through out the day Thursday.  On Friday, most symptoms had resolved but he still had a slight headache and was slightly lightheaded.  By Friday evening those remaining symptoms resolved.  The only symptom that did not resolve was the soreness at the injection site.  That symptom resolved by Sunday night.  ~~~~~~~Consented to follow up.Call Notes:The vaccine was administered at Pharmacy
his voice is a little raspy; diarrhea; nausea; This is a spontaneous report from a contactable consumer (Patient) via Medical Information Team. A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on 18Feb2021 at 10:30 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medication was not reported. It was reported that the patient would be off the blood thinner (unspecified) very soon. On 18Feb2021, same day of vaccination at 23:30, the patient experienced diarrhoea, nausea, and on 19Feb2021, his voice was a little raspy. The patient reported that his voice is a little raspy on the day of reporting. He got his 1st dose of the vaccine about 10:30 am yesterday (18Feb2021), and after getting the shot they gave him a packet of information. States that they really should have given him the information before giving the injection because he discovered that the packet says to tell someone if you are on blood thinners. States that no one asked him if he was on a blood thinner, and he didn't know that was something he should have told them. Will that make a difference since he already had the shot. States that he will be off the blood thinner very soon. Also states that about 11:30 pm that night, 13 hours post vaccination, he started having diarrhea and was nauseous. It might have been something he ate but could those be side effects from the vaccine and if so, can anyone else catch his side effects. Patient wants to know if these side effects are related to the vaccine. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Received VAX Thurs afternoon - Sat. AM itched arm at site of injection and a dime-sized blister broke open. Did not feel ill or notice anything until Sat. AM.
Extreme irritability beginning vaccine administration. Bouts of inconsolable crying; lasted weeks per parent. No fever. Decreased appetite for weeks, no fever or other symptoms.
Patient suffers from chronic tinnitus due to Cholesteatoma both ears.   I was out of flying for 2.5 years due to shoulder injury. Came back to flying in March.  Took the J and J in late March.  I have had tinnitus for years and noticed it has gotten worse since my last flights in 2018.  I just assumed it was age related increase and may well be but the volume and intensity of my tinnitus is much worse since the Vax.    I recently heard about this  and this morning did some research and found that others have reported getting tinnitus following the vax and some report worsening conditions.  I will be seeing my doctor next week to discuss but for now, there has been no meetings with healthcare professionals.
Information has been received from a nurse practitioner concerning a 16 weeks old female child who on 25-OCT-2011 was vaccinated intramuscularly with a dose of ROTATEQ (lot #, dose not reported). She had not yet seen the patient or contacted the clinic where the patient was treated but was told by the patient's mother that it occurred. She was going to follow-up with the clinic before she saw the patient and called back with a follow-up report. No Adverse events reported. At 5:00 PM on 25-OCT-2011 follow up AE information: the nurse practitioner reported that she examined the child "today" on 25-OCT-2011, in a separate clinic. The child displayed some irritability and a small local reaction at the injection site, as well as a low grade fever. She did not think these findings were unusual, since the patient received numerous vaccines "yesterday" on 24-OCT-2011. Otherwise, she seemed fine. The patient was seen by the doctor on 24-OCT-2011. The patient's mother called and was bringing child in to seek medical attention. At the time of reporting outcome was unknown. Follow up information has been received from the nurse practitioner concerning the 16 weeks old female with no allergies, medical conditions, illness at the time of vaccination or adverse events following prior vaccinations who at 11:00 AM on 25-OCT-2011 was vaccinated intramuscularly on left anterior thigh with a first dose of ROTATEQ (lot #, dose not reported) in another clinic. The patient experienced small nodule with some erythema to left anterior thigh at injection site. The patient was seen in clinic at 2:00 pm on 26-OCT-2011 and again at 10:00 am on 28-OCT-2011. No treatment was needed. The patient recovered from the events on 28-OCT-2011. The patient was revaccinated by mouth with a 2 ml second dose of ROTATEQ (lot # not reported) in another clinic on 23-NOV-2011. The patient did not seek medical attention. Additional information has been requested.
Muscle aches, headache, stomach upset, diarrhea, complete fatigue, fever and chills.
This was Varicella zoster (Shingrix).  I had body aches, headache (it seemed like a sinus headache, which is weird), fogginess, and a particularly sore arm.  These symptoms lasted for a little over a day.  I could mostly manage them with acetaminophen, but they were bad enough to interfere with my day.
I tested positive for COVID-19. I had a slight cough; hip aches; felt crummy. I talked to the doctor and got an infusion. My symptoms lasted for 4 days.
Developed patchy rashes at injection site, elbows, knees, fingers, toes, and hips.
Developed 3 singular, isolated, red, raised "spots": (L) neck; (R) neck and (R) shoulder on 12/17/14.
IM Flu vaccine (lot#AFLUA120AA) given on 10/10/2005. Between 10/11 to 10/13 the patient experienced nausea and vomiting. On 10/13 the patient experienced coffee-ground emesis. On 10/14 the patient expired. Cause of death pending medical examiner report.
A few days after the second vaccination, patient started feeling poorly. Shortness of breath, tiredness and could not shake it.  Ended up at hospital and after multiple tests he was flown to another hospital with a pulmonary embolism.  He is currently in hospital being treated for PE and multiple clots in his legs.
UTI; some issues with continuing to empty bladder; This is a spontaneous report from a contactable consumer (patient herself). A 38-years-old female patient received first dose of bnt162b2 (BNT162B2, Solution for injection, Batch/Lot Number: EW0180) via an unspecified route of administration at (upper) arm left (at the age of 38-year-old) on 07Jun2021 10:00 as single dose for covid-19 immunisation. Medical history included ongoing ehlers-danlos syndrome (she was diagnosed with this many many years ago since it is genetic). Concomitant medications were not reported. The patient had no AE and Prior Vaccinations (within 4 weeks). On 07Jun2021, patient had first dose last week on Monday which was given at approximately 10:00 am and by late afternoon and after that she reported that she had some issues with continuing to empty her bladder which resulted in really bad UTI and she has been struggling with it ever since. The patient stated this significantly worsened and so she saw an urgent care doctor and they were not sure if the antibiotics would be strong enough because there was a possibility of it going to her kidneys. The patient also stated for UTI, it has improved since getting (unspecified) antibiotics. The patient did not visit to emergency room. The patient went to the urgent care. The outcome of the event some issues with continuing to empty bladder was not recovered and urinary tract infection was recovering.   No follow-up attempts are possible. No further information is expected.
The day after receiving the shot I began to itch all over. Within 3 days, I began breaking out in hives. Within the first week, I had terrible gas/ bloating and pressure/ pain in my spine. Gas felt like it was trapped in my body.  After 2 weeks, I began feeling side stitches and pressure/ pain in my stomach. I had these random pressure/ pains in my right side of my abdomen. At 2 weeks and 1 day, I had some pretty prominent veins show up on my right breast. The next day, I had chest pains that started in my right side of my chest and then moved to my left side. After 3 weeks and 3 days from when I got the shot (and when my period ended), the internal turbulence in my abdomen stopped.
Really severe lower back pain. Started after getting the first dose Feb 8th and I still have it now.
Injection site pain in left arm (started at 7pm 4/1/21, ended 4/3/21 around 12pm)  Redness around injection and across left shoulder, injection site/left shoulder felt very hot  (started around AM of 4/2/21 - exact time uncertain).  Slight chills (started around 3AM 4/02/21, ended shortly after)  *Skin sensitivity - My upper torso (arms, chest, back, shoulder, neck, and abdomen) felt hyper-sensitive to all touch (not painful, but significantly uncomfortable). This started around 11AM 4/02/21 and ended around 9AM 4/03/21.  Slight shortness of breath - not significant or burdensome. (Started 4/01/21 around 9PM, ended around 10PM 4/02/21).   No other symptoms to 2nd dose of Pfizer. All symptoms were gone by 4/03/21.   Took 1 Tylenol tablet around 11AM 4/02/2021 for injection site/left arm pain.
Vial was first punctured on 15-Nov-2022 and administered on 17-Nov-2022; No adverse event; Administered Moderna Covid-19 Vaccine, Bivalent after the 12 hr period; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered Moderna Covid-19 Vaccine, Bivalent after the 12 hr period), PRODUCT STORAGE ERROR (Vial was first punctured on 15-Nov-2022 and administered on 17-Nov-2022) and NO ADVERSE EVENT (No adverse event) in an 81-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 020H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 17-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered Moderna Covid-19 Vaccine, Bivalent after the 12 hr period). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was first punctured on 15-Nov-2022 and administered on 17-Nov-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered Moderna Covid-19 Vaccine, Bivalent after the 12 hr period), PRODUCT STORAGE ERROR (Vial was first punctured on 15-Nov-2022 and administered on 17-Nov-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Administered Moderna Covid-19 Vaccine, Bivalent after the 12 hr period) and PRODUCT STORAGE ERROR (Vial was first punctured on 15-Nov-2022 and administered on 17-Nov-2022).    Concomitant medication was not provided.  Nurse reported that only 2 doses were administered from the vail and size was 2.5 ml. The vial was first punctured on 15-Nov-2022 and was administered to patient on 16-Nov-2022 and 17-Nov-2022. The vial was stored post puncture in refrigerator. The vial did not undergo any temperature excursion.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-679118 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-679118:
Subsequent to receiving one dose of varicella virus vaccine live the pt developed approximately 40 lesions rash with loose stool. The rashes were located on his buttock area, face and abdomen. Two days post onset the pt recovered.
Extreme fatigue, extreme headache, fever 100.8, arm and chest numbness, sensitivity to light and sounds, bruising along lower arm.
Cannot turn the neck, needs to turn whole body to look right; Pain in right side of neck, Debilitating pain; Sore arm; Arm red; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL DISCOMFORT (Cannot turn the neck, needs to turn whole body to look right), NECK PAIN (Pain in right side of neck, Debilitating pain), INJECTION SITE PAIN (Sore arm) and INJECTION SITE ERYTHEMA (Arm red) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     Concomitant products included DICLOFENAC for an unknown indication.    On 26-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MUSCULOSKELETAL DISCOMFORT (Cannot turn the neck, needs to turn whole body to look right), NECK PAIN (Pain in right side of neck, Debilitating pain), INJECTION SITE PAIN (Sore arm) and INJECTION SITE ERYTHEMA (Arm red). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MUSCULOSKELETAL DISCOMFORT (Cannot turn the neck, needs to turn whole body to look right), NECK PAIN (Pain in right side of neck, Debilitating pain), INJECTION SITE PAIN (Sore arm) and INJECTION SITE ERYTHEMA (Arm red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Weeks later after the vaccine my hand started randomly shaking and I am unable to write my name. On 2/24 I went to the doctor and they said they can't figure out why my hands keep shaking so they recommended me to go to a neurologist and I have a appointment this upcoming week.
I had a stuffing nose, cough, scratchy throat, and headache. I tested positive for COVID-19  and called my doctor. My doctor prescribed me Albuterol Benzonatate, and Flonase.
Pt. received flu vaccine and immediately had itchy feeling. Noticed rash to forehead/eyelids and neck the following day.
Initial case retrieved via a search of the scientific literature on 24 April 2014. ABSTRACT OBJECTIVE: Live vaccines are generally contraindicated in patients with DiGeorge syndrome (DGS), a congenital disorder characterized by cellular immune deficiency. Vaccine utilization and safety in this population are not well described. This study examined vaccination patterns and adverse events following live immunization (AEFLI) in these individuals. METHODS: A multicenter retrospective cohort study was conducted in subjects with DGS confirmed by fluorescence in situ hybridization assay (chromosome 22q11.2 microdeletion). Live vaccine-preventable illnesses, vaccination coverage and timeliness, and AEFLIs in the 56-day window after live vaccination were examined. Bivariate and multivariable analyses assessed the impact of demographics medical history, timing of diagnostic confirmation, and preceding immune function on vaccination patterns and AEFLIs. RESULTS: Of 194 subjects, 77% and 75% received measles-mumps-rubella (MMR) and varicella vaccines, respectively; 58% completed recommended vaccinations by age 19 to 35 months. Adverse events occurred after 14% and 20% of MMR and varicella vaccine doses, respectively. Most events were minor, few were serious, and no deaths were reported in post-live vaccination windows. Although early diagnostic confirmation negatively affected live vaccination coverage and timeliness (P < .001), baseline CD4% did not differ between subjects who did or did not receive live vaccines by 12 to 18 months. Among varicella vaccine recipients, those with a subsequent adverse event had a lower preceding CD4% (24.8% + or - 7.3%) than those without (35.5% + or - 11.7%) (P < .05); no CD4% differences were observed with MMR vaccination. Fourteen unvaccinated subjects experienced live vaccine-preventable illnesses. CONCLUSIONS: Live vaccines were frequently given and generally well tolerated among patients with DGS with mild-to-moderate immunosuppression. A patient (gender and age not reported) with a history of DiGeorge syndrome received the following vaccines on an unspecified date: DTaP vaccine  (manufacturer not reported), HIB vaccine (manufacturer not reported), MMR vaccine (other manufacturer) and Varicella vaccine (Live) (other manufacturer). Five days post-vaccination, the patient experienced seizure and a fever and was seen in the emergency department. Five days later, i.e. 10 days post-vaccination, the patient was seen again in the emergency department with a fever and was diagnosed with otitis media. Outcome was not reported. Documents held by sender: None.
temp >103 x 3 days began 27JUN97;rash, itching & conjunctivitis 30JUN97;
Hearing loss, auditory abnormalities, cranial swelling and it caused me to have an extra menstrual cycle (that never happens to me).
pt recv vax 10DEC97 & 14DEC97 elevated temp, poor appetite, weakness;15DEC97 inc temp taken to hosp adm;16DEC97 inc temp convuls, diff breathing taken to hosp;17DEC97 dec temp condition unresponsive & unable to communicate;
Rapid acceleration in pulse rate at high of 104; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of HEART RATE INCREASED (Rapid acceleration in pulse rate at high of 104) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No medical history information was provided.  Concomitant products included METOPROLOL for an unknown indication.    On 26-Jan-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced HEART RATE INCREASED (Rapid acceleration in pulse rate at high of 104). At the time of the report, HEART RATE INCREASED (Rapid acceleration in pulse rate at high of 104) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, Heart rate: 104 (High) experienced rapid acceleration in pulse rate at high of 104.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patients HCP advised him to monitor(pulse rate), and drink lots of fluid.; Sender's Comments: Very limited information regarding this event has been provided at this time.  Further information has been requested.
Expired vaccine used; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine used).    Treatment medication was not provided Concomitant medication was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-704335 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704335:MASTER CASE